{"id":323757,"date":"2026-10-22T12:40:58","date_gmt":"2026-10-22T07:10:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=323757"},"modified":"2026-10-22T12:40:58","modified_gmt":"2026-10-22T07:10:58","slug":"tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/","title":{"rendered":"3 Tertiary Care Hospitals, Preventive Health Testing and Large Hospital Chains Stocks With a Strong Future Roadmap: Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise: ROE of 14.1% to 27.9% and FY22 to FY26 revenue CAGR of 8.2% to 19.6%. Prices as of 21 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three hospital and preventive diagnostics stocks to watch are Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise. Their return on equity ranges from 14.1% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 19.6%. Thyrocare Technologies has the highest return on equity at 27.9%, while Global Health has the fastest revenue growth at 19.6% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Hospital and preventive diagnostics stocks let investors follow providers of complex treatment and the labs that support early detection. Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise cover tertiary care hospitals, preventive health testing and one of the largest hospital chains.<\/p>\n<p>This list covers three hospital and preventive diagnostics stocks with complete current figures: Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#What_Are_Hospital_and_Preventive_Diagnostics_Stocks\" title=\"What Are Hospital and Preventive Diagnostics Stocks?\">What Are Hospital and Preventive Diagnostics Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Hospital_and_Preventive_Diagnostics_Stocks_at_a_Glance\" title=\"Hospital and Preventive Diagnostics Stocks at a Glance\">Hospital and Preventive Diagnostics Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Why_Do_Hospital_and_Preventive_Diagnostics_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Hospital and Preventive Diagnostics Stocks Have a Strong Roadmap in India?\">Why Do Hospital and Preventive Diagnostics Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Why_Global_Health_Features_Among_These_Hospital_and_Preventive_Diagnostics_Stocks\" title=\"Why Global Health Features Among These Hospital and Preventive Diagnostics Stocks\">Why Global Health Features Among These Hospital and Preventive Diagnostics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Why_Thyrocare_Technologies_Features_Among_These_Hospital_and_Preventive_Diagnostics_Stocks\" title=\"Why Thyrocare Technologies Features Among These Hospital and Preventive Diagnostics Stocks\">Why Thyrocare Technologies Features Among These Hospital and Preventive Diagnostics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Why_Apollo_Hospitals_Enterprise_Features_Among_These_Hospital_and_Preventive_Diagnostics_Stocks\" title=\"Why Apollo Hospitals Enterprise Features Among These Hospital and Preventive Diagnostics Stocks\">Why Apollo Hospitals Enterprise Features Among These Hospital and Preventive Diagnostics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Global_Health_vs_Thyrocare_Technologies_vs_Apollo_Hospitals_Enterprise_on_Key_Financials\" title=\"Global Health vs Thyrocare Technologies vs Apollo Hospitals Enterprise on Key Financials\">Global Health vs Thyrocare Technologies vs Apollo Hospitals Enterprise on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Key_Risks_to_Check_Before_Investing_in_Hospital_and_Preventive_Diagnostics_Stocks\" title=\"Key Risks to Check Before Investing in Hospital and Preventive Diagnostics Stocks\">Key Risks to Check Before Investing in Hospital and Preventive Diagnostics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Final_Thoughts_on_Hospital_and_Preventive_Diagnostics_Stocks\" title=\"Final Thoughts on Hospital and Preventive Diagnostics Stocks\">Final Thoughts on Hospital and Preventive Diagnostics Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#What_are_hospital_and_preventive_diagnostics_stocks\" title=\"What are hospital and preventive diagnostics stocks?\">What are hospital and preventive diagnostics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Which_hospital_and_preventive_diagnostics_stocks_are_covered_in_this_list\" title=\"Which hospital and preventive diagnostics stocks are covered in this list?\">Which hospital and preventive diagnostics stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Why_do_hospital_and_preventive_diagnostics_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do hospital and preventive diagnostics stocks have a strong future roadmap in India?\">Why do hospital and preventive diagnostics stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#How_has_Global_Health_performed_financially\" title=\"How has Global Health performed financially?\">How has Global Health performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#How_has_Thyrocare_Technologies_performed_financially\" title=\"How has Thyrocare Technologies performed financially?\">How has Thyrocare Technologies performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#How_has_Apollo_Hospitals_Enterprise_performed_financially\" title=\"How has Apollo Hospitals Enterprise performed financially?\">How has Apollo Hospitals Enterprise performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#What_risks_should_investors_check_before_buying_hospital_and_preventive_diagnostics_stocks\" title=\"What risks should investors check before buying hospital and preventive diagnostics stocks?\">What risks should investors check before buying hospital and preventive diagnostics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains-stocks-roadmap-harbinger-list\/#Is_this_list_of_hospital_and_preventive_diagnostics_stocks_investment_advice\" title=\"Is this list of hospital and preventive diagnostics stocks investment advice?\">Is this list of hospital and preventive diagnostics stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Hospital_and_Preventive_Diagnostics_Stocks\"><\/span><strong>What Are Hospital and Preventive Diagnostics Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hospital and preventive diagnostics stocks are listed companies that run large hospitals and diagnostic labs. Their earnings depend on bed capacity, occupancy, test volumes and the share of complex procedures.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Hospital_and_Preventive_Diagnostics_Stocks_at_a_Glance\"><\/span><strong>Hospital and Preventive Diagnostics Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/medanta\/global-health-ltd-share-price-today\">Global Health<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,232.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,277<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">60.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.30<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/thyrocare\/thyrocare-technologies-ltd-share-price-today\">Thyrocare Technologies<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">456.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,501<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">42.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.09<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/apollohosp\/apollo-hospitals-enterprise-ltd-share-price-today\">Apollo Hospitals Enterprise<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,600<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">110,757<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">51.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.90<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Thyrocare Technologies and Apollo Hospitals Enterprise trade at a P\/E below the industry P\/E, while Global Health trades above it, which reflects the growth the market already expects. Readers comparing hospital and preventive diagnostics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital and preventive diagnostics stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Hospital_and_Preventive_Diagnostics_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Hospital and Preventive Diagnostics Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hospital and preventive diagnostics stocks have a strong roadmap in India because demand for advanced treatment and early testing is rising faster than the supply of organised capacity.<\/p>\n<ul>\n<li><strong>Complex procedures.<\/strong> Tertiary care lifts revenue per patient.<\/li>\n<li><strong>Health awareness.<\/strong> More people opt for regular preventive tests.<\/li>\n<li><strong>Digital reach.<\/strong> Online booking and home collection widen the customer base.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Global_Health_Features_Among_These_Hospital_and_Preventive_Diagnostics_Stocks\"><\/span><strong>Why Global Health Features Among These Hospital and Preventive Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the hospital and preventive diagnostics stocks on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.<\/p>\n<p>The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P\/E of 60.3, above the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.<\/p>\n<p><strong>What to watch:<\/strong> Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Thyrocare_Technologies_Features_Among_These_Hospital_and_Preventive_Diagnostics_Stocks\"><\/span><strong>Why Thyrocare Technologies Features Among These Hospital and Preventive Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the north India hospital shares on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.<\/p>\n<p>Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%.<\/p>\n<p>In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.<\/p>\n<p><strong>What to watch:<\/strong> Track growth in test volume per day and the share of revenue from preventive health packages.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Apollo_Hospitals_Enterprise_Features_Among_These_Hospital_and_Preventive_Diagnostics_Stocks\"><\/span><strong>Why Apollo Hospitals Enterprise Features Among These Hospital and Preventive Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Apollo Hospitals Enterprise is India&#8217;s largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.<\/p>\n<p>In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%.<\/p>\n<p>Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P\/E of 51.0, below the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.<\/p>\n<p><strong>What to watch:<\/strong> Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Global_Health_vs_Thyrocare_Technologies_vs_Apollo_Hospitals_Enterprise_on_Key_Financials\"><\/span><strong>Global Health vs Thyrocare Technologies vs Apollo Hospitals Enterprise on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three hospital and preventive diagnostics stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Global Health<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,206<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,509<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">554<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Thyrocare Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">618<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">846<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">163<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Apollo Hospitals Enterprise<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,741<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25,420<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,003<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.9%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Apollo Hospitals Enterprise has the largest FY26 revenue at Rs 25,420 crore, and Global Health shows the fastest revenue growth with a 19.6% compound annual rate. A useful habit with hospital and preventive diagnostics stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Global Health<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,051<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,326<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Thyrocare Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">198<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">244<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Apollo Hospitals Enterprise<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,882<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,092<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Hospital_and_Preventive_Diagnostics_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Hospital and Preventive Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these hospital and preventive diagnostics stocks, the main points are: Long-term north India hospital shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Ramp-up timing.<\/strong> New hospitals take time to reach stable utilisation.<\/li>\n<li><strong>Doctor availability.<\/strong> Expert doctors are central to growth and hard to attract.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter hospital and preventive diagnostics stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Hospital_and_Preventive_Diagnostics_Stocks\"><\/span><strong>Final Thoughts on Hospital and Preventive Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hospital and preventive diagnostics stocks reward investors who follow bed additions, occupancy and test volumes together. Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise each serve a growing patient base. Based on the 21 October 2026 close, Global Health trades at Rs 1,232.4, Thyrocare Technologies at Rs 456.2 and Apollo Hospitals Enterprise at Rs 7,600. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these hospital and preventive diagnostics stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track hospital and preventive diagnostics stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_hospital_and_preventive_diagnostics_stocks\"><\/span><strong>What are hospital and preventive diagnostics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Hospital and preventive diagnostics stocks are listed companies that run large hospitals and diagnostic labs. Their earnings depend on bed capacity, occupancy, test volumes and the share of complex procedures. This list looks at three of them, Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_hospital_and_preventive_diagnostics_stocks_are_covered_in_this_list\"><\/span><strong>Which hospital and preventive diagnostics stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise. Based on the 21 October 2026 close, Global Health traded at Rs 1,232.4, Thyrocare Technologies at Rs 456.2 and Apollo Hospitals Enterprise at Rs 7,600. Their return on equity ranges from 14.1% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 19.6%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_hospital_and_preventive_diagnostics_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do hospital and preventive diagnostics stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Hospital and preventive diagnostics stocks have a strong roadmap in India because demand for advanced treatment and early testing is rising faster than the supply of organised capacity. The main drivers are as follows. Complex procedures. Tertiary care lifts revenue per patient. Health awareness. More people opt for regular preventive tests. Digital reach. Online booking and home collection widen the customer base. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Global_Health_performed_financially\"><\/span><strong>How has Global Health performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P\/E of 60.3, above the industry P\/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Thyrocare_Technologies_performed_financially\"><\/span><strong>How has Thyrocare Technologies performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Apollo_Hospitals_Enterprise_performed_financially\"><\/span><strong>How has Apollo Hospitals Enterprise performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P\/E of 51.0, below the industry P\/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_hospital_and_preventive_diagnostics_stocks\"><\/span><strong>What risks should investors check before buying hospital and preventive diagnostics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying hospital and preventive diagnostics stocks. Ramp-up timing. New hospitals take time to reach stable utilisation. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_hospital_and_preventive_diagnostics_stocks_investment_advice\"><\/span><strong>Is this list of hospital and preventive diagnostics stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are hospital and preventive diagnostics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Hospital and preventive diagnostics stocks are listed companies that run large hospitals and diagnostic labs. Their earnings depend on bed capacity, occupancy, test volumes and the share of complex procedures. This list looks at three of them, Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which hospital and preventive diagnostics stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise. Based on the 21 October 2026 close, Global Health traded at Rs 1,232.4, Thyrocare Technologies at Rs 456.2 and Apollo Hospitals Enterprise at Rs 7,600. Their return on equity ranges from 14.1% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 19.6%.\"}},{\"@type\":\"Question\",\"name\":\"Why do hospital and preventive diagnostics stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Hospital and preventive diagnostics stocks have a strong roadmap in India because demand for advanced treatment and early testing is rising faster than the supply of organised capacity. The main drivers are as follows. Complex procedures. Tertiary care lifts revenue per patient. Health awareness. More people opt for regular preventive tests. Digital reach. Online booking and home collection widen the customer base. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Global Health performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P\/E of 60.3, above the industry P\/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.\"}},{\"@type\":\"Question\",\"name\":\"How has Thyrocare Technologies performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.\"}},{\"@type\":\"Question\",\"name\":\"How has Apollo Hospitals Enterprise performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P\/E of 51.0, below the industry P\/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying hospital and preventive diagnostics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying hospital and preventive diagnostics stocks. Ramp-up timing. New hospitals take time to reach stable utilisation. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of hospital and preventive diagnostics stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hospital and Preventive Diagnostics Stocks with a strong future roadmap: Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.<\/p>\n","protected":false},"author":35,"featured_media":323756,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[14049,3803,7544,14773,14771,14772,9126],"class_list":["post-323757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-apollo-hospitals-enterprise","tag-best-stocks","tag-global-health","tag-health-check-lab-stocks","tag-hospital-and-preventive-diagnostics-stocks","tag-north-india-hospital-shares","tag-thyrocare-technologies"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["323756"],"rank_math_title":["Hospital and Preventive Diagnostics Stocks"],"rank_math_description":["Compare 3 hospital and preventive diagnostics stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 21 Oct 2026."],"rank_math_focus_keyword":["hospital and preventive diagnostics stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-tertiary-care-hospitals-preventive-health-testing-and-large-hospital-chains.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=323757"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323757\/revisions"}],"predecessor-version":[{"id":323758,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323757\/revisions\/323758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/323756"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=323757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=323757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=323757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}